$9.25−0.33 (−3.44%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD
VIR Biotechnology (VIR) Income Statement
Is this a real, growing, cash-generative business, or a story propped up by accounting?
Sources Company filings FilingsHow we compute thisNot investment advice
38 figures withheld by our checks. Each blank figure names its reason.
Business engineChoppy: revenue is 96% below its peak, net margin −638.9%.
The four lines that matter · FY21–FY25
Revenue ($M)▼7.6%
68.6
FY21→FY25CAGR −50.0%/yr
Net income ($M)▲16.1%
−438.0
one-off year: see footnoteCAGR —
Free cash flow ($M)▲12.6%
−396.6
FY21→FY25CAGR —
Diluted EPS▲17.5%
−3.16
FY21→FY25CAGR —
What the receipts whisper · what a headline number hides
Share count
+3.8%
133.4mn → 138.5mn diluted shares since FY21. Broadly flat, so EPS moves with net income rather than with the share count.
Capex
$4.8M
−33.8% YoY in FY25 · 7.0% of revenue.
What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($K)
-639¢ of every revenue dollar becomes profit. The biggest cost lever is operating expenses.
Margin trend · direction beats level Gross Operating Net
Net margin -638.9% is below the sector median.
The receipt · income statement · FY21–FY25 USD thousands except per-share & ratios · hover a line for its definition
USD thousands except per-share & ratios
| Line item | TTM † | FY25 | FY24 | FY23 | FY22 | FY21 | YoY | CAGR 21→25 |
|---|---|---|---|---|---|---|---|---|
| Revenue & profitability | ||||||||
Revenue | 302,828.0 | 68,556.0 | 74,205.0 | 86,180.0 | 1,615,797.0 | 1,095,415.0 | ▼7.6% | −50.0% |
Cost of revenue | 15.0 | 26.0 | 845.0 | 2,765.0 | 146,319.0 | 65,865.0 | ▼96.9% | −85.9% |
Gross profit | 302,813.0 | —A | 73,360.0 | 83,415.0 | 1,469,478.0 | 1,029,550.0 | — | — |
Research & development | 412,594.0 | 455,966.0 | 506,499.0 | 579,720.0 | 474,648.0 | 448,006.0 | ▼10.0% | +0.4% |
Selling, general & admin | 101,581.0 | 92,074.0 | 119,031.0 | 174,441.0 | 161,762.0 | 160,793.0 | ▼22.6% | −13.0% |
Total operating expenses | 514,186.0 | 547,858.0 | 660,525.0 | 767,720.0 | 636,410.0 | 608,799.0 | ▼17.1% | −2.6% |
Operating incomefeeds ROC rank | −211,402.0 | −479,328.0 | −587,165.0 | −684,305.0 | 833,068.0 | 420,751.0 | ▲18.4% | — |
Other income, net | 26,681.0 | 41,558.0 | 64,060.0 | 56,111.0 | −78,788.0 | 129,051.0 | — | — |
Pretax income | −184,721.0 | −437,770.0 | −523,105.0 | −628,194.0 | 754,280.0 | 549,802.0 | ▲16.3% | — |
Income tax | 69.0 | 217.0 | −1,145.0 | −13,077.0 | 238,443.0 | 21,218.0 | — | −68.2% |
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings | −184,790.0 | −437,987.0 | −521,960.0 | −615,061.0 | 515,837.0 | 528,584.0 | ▲16.1% | — |
| Per share | ||||||||
Diluted EPSbuyback-sensitive | −1.26 | −3.16 | −3.83 | −4.59 | 3.83 | 3.96 | ▲17.5% | — |
Diluted shares (mn) | 169.28 | 138.52 | 136.25 | 134.13 | 134.81 | 133.44 | ▲1.7% | +0.9% |
| Margins | ||||||||
Gross margin100th pct in Healthcare | 100.0% | —A | 98.9% | 96.8% | 90.9% | 94.0% | — | — |
Operating margin | −69.8% | −699.2% | −791.3% | −794.0% | 51.6% | 38.4% | ▲92.1pp | −737.6pp |
Net margin13th pct in Healthcare | −61.0% | −638.9% | −703.4% | −713.7% | 31.9% | 48.3% | ▲64.5pp | −687.1pp |
† TTM = trailing four quarters through 2026-09-30.FY22 effective tax rate was 32% vs a 2% norm for this window, likely a one-time item; see the filing.A Withheld: this year's gross margin is not on the same cost basis as the earlier years.
4 more years of statements and CSV export are on Premium.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
These lines feed the tenet checklists: see which gates passTenets →Margins & returns continue as sector-ranked ratiosStatistics →
Annual report filed 2026-02-23 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.
Statements normalized in our fundamentals DB · Not investment advice.
Common questions
What was VIR Biotechnology's revenue last fiscal year?
VIR Biotechnology reported revenue of $68.6M in fiscal 2025, down 7.6% from fiscal 2024.
What was VIR Biotechnology's net income?
VIR Biotechnology reported net income of −$438.0M in fiscal 2025, a net margin of −638.9%.
Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

